Business Context and Reporting Period
Tiziana Life Sciences Ltd. filed this Form 6-K on October 25, 2024. The filing announces the entry into a new Open Market Sale Agreement (ATM) with Jefferies LLC to facilitate the potential sale of common shares.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It is a disclosure of a financing arrangement rather than a financial results report.
- Maximum Offering Size: Up to $50.0 million in aggregate offering price.
- Commission Rate: 3.0% of gross proceeds payable to Jefferies LLC.
- Previous ATM Termination: The prior agreement with B. Riley Securities, Inc. was terminated effective October 21, 2024.
Material Changes
The primary material change is the replacement of the sales agent for the company's at-the-market offering program. The company terminated its agreement with B. Riley Securities, Inc. and entered into a new agreement with Jefferies LLC to manage the sale of up to $50.0 million of common shares.
Guidance, Outlook, and Use of Proceeds
Management intends to use the net proceeds from any shares sold under the new ATM Agreement for the following purposes:
- Completing the Phase 2a clinical trial for the intra-nasal delivery of foralumab in patients with non-active secondary progressive multiple sclerosis.
- Expediting the clinical development of foralumab in Alzheimer's disease.
- Developing foralumab for other indications.
- Working capital and general corporate purposes.
The company has no obligation to sell any shares and may suspend the offering at any time.
Investor Verification Checklist
- Verify the current cash position and runway to determine the urgency of utilizing the new ATM facility.
- Monitor the status of the Phase 2a clinical trial for foralumab in multiple sclerosis.
- Track any actual sales of shares under the new Jefferies agreement and the resulting dilution.
- Review the terminated B. Riley agreement terms to understand the context of the switch in sales agents.